Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03047993 · FLOW

Participant flow

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome · Source last updated 2024-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7. Azacitidine: Given IV or SC Glutaminase Inhibitor CB-839: Given PO
    id
    FG000
    title
    Treatment (Glutaminase Inhibitor CB-839, Azacitidine)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7. Azacitidine: Given IV or SC Glutaminase Inhibitor CB-839: Given PO
    id
    FG000
    title
    Treatment (Glutaminase Inhibitor CB-839, Azacitidine)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        28
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice